Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 85, Issue , 2018, Pages 32-37

  Garvey, W Timothy ^a   Van Gaal, Luc ^b   Leiter, Lawrence A ^c   Vijapurkar, Ujjwala ^d   List, James ^d   Cuddihy, Robert ^d   Ren, Jimmy ^d   Davies, Michael J ^d  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adipokines; Adipose tissue; Biomarkers; Chemokines; Sodium glucose co transporter 2 inhibitors; Type 2 diabetes mellitus

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANAGLIFLOZIN; GLIMEPIRIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; METFORMIN; MOLYBDENUM IRON PROTEIN; SULFONYLUREA DERIVATIVE;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT; BODY WEIGHT LOSS; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FAT MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; AGED; BLOOD; CLINICAL TRIAL; INFLAMMATION; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADIPONECTIN; AGED; BIOMARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION; LEPTIN; MALE; METFORMIN; MIDDLE AGED; MOLYBDOFERREDOXIN; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85044500198     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2018.02.002     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention, Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988–1994 and 1999–2002. MMWR Morb Mortal Wkly Rep 53 (2004), 1066–1068.
2. Van Gaal, L.F., Mertens, I.L., De Block, C.E., Mechanisms linking obesity with cardiovascular disease. Nature 444 (2006), 875–880.
3. Berg, A., Scherer, P., Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005), 939–949.
4. Blüher, M., Mantzoros, C.S., From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metab Clin Exper 64 (2015), 131–145.
5. Fasshauer, M., Bluher, M., Adipokines in health and disease. Trends Pharmacol Sci 36 (2015), 461–470.
6. Tian, L., Luo, N., Klein, R.L., Chung, B.H., Garvey, W.T., Fu, Y., Adiponectin reduces lipid accumulation in macrophage foam cells. Atherosclerosis 202 (2009), 152–161.
7. Fu, Y., Luo, N., Klein, R.L., Garvey, W.T., Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 46 (2005), 1369–1379.
8. Lara-Castro, C., Fu, Y., Chung, B.H., Garvey, W.T., Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease. Curr Opin Lipidol 18 (2007), 263–270.
9. Bailey, C.J., Iqbal, N., T'Joen, C., List, J.F., Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab 14 (2012), 951–959.
10. Blüher, M., Rudich, A., Kloting, N., Goland, R., Henkin, Y., Rubin, E., et al. Two patterns of adipokine and other biomarker dynamics in a long-term weight loss intervention. Diabetes Care 35 (2012), 342–349.
11. Van Gaal, L.F., Wauters, M.A., Mertens, I.L., Considine, R.V., De Leeuw, I.H., Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord 23:Suppl. 1 (1999), 29–36.
12. Kargulewicz, A., Szulinska, M., Kujawska-Luczak, M., Swora-Cwynar, E., Musialik, K., Grzymislawska, M., et al. Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat – a prospective randomized open-label trial. Eur Rev Med Pharmacol Sci 20 (2016), 3868–3876.
13. Rosenthal, N., Meininger, G., Ways, K., Polidori, D., Desai, M., Qiu, R., et al. Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus. Ann N Y Acad Sci 1358 (2015), 28–43.
14. Cefalu, W.T., Leiter, L.A., Yoon, K.H., Arias, P., Niskanen, L., Xie, J., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382 (2013), 941–950.
15. Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
16. Inzucchi, S.E., Zinman, B., Wanner, C., Ferrari, R., Fitchett, D., Hantel, S., et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 12 (2015), 90–100.
17. Motomura, T., Okamoto, M., Kitamura, T., Yamamoto, H., Otsuki, M., Asanuma, N., et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 16 (2009), 546–552.
18. Bhattacharya, S.K., Madan, M., Mahajan, P., Paudel, K.R., Rauniar, G.P., Das, B.P., et al. Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride. Indian J Physiol Pharmacol 52 (2008), 43–52.
19. Nakamura, I., Oyama, J., Komoda, H., Shiraki, A., Sakamoto, Y., Taguchi, I., et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc Diabetol, 13, 2014, 15.
20. Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 715 (2013), 246–255.
21. Ferrannini, E., Ramos, S.J., Salsali, A., Tang, W., List, J.F., Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 33 (2010), 2217–2224.
22. Matsumura, M., Nakatani, Y., Tanka, S., Aoki, C., Sagara, M., Yanagi, K., et al. Efficacy of additional canagliflozin administration to type 2 diabetes patients receiving insulin therapy: examination of diurnal glycemic patterns using continuous glucose monitoring (CGM). Diabetes Ther 8 (2017), 821–827.
23. Lopez-Jaramillo, P., Gomez-Arbelaez, D., Lopez-Lopez, J., Lopez-Lopez, C., Martinez-Ortega, J., Gomez-Rodriguez, A., et al. The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 18 (2014), 37–45.
24. Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
25. Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 124 (2014), 509–514.
26. Yu, J.G., Javorschi, S., Hevener, A.L., Kruszynska, Y.T., Norman, R.A., Sinha, M., et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 51 (2002), 2968–2974.
27. Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
28. Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.
29. Luo, N., Chung, B.H., Wang, X., Klein, R.L., Tang, C.K., Garvey, W.T., et al. Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis 228 (2013), 124–135.
30. Luo, N., Liu, J., Chung, B.H., Yang, Q., Klein, R.L., Garvey, W.T., et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 59 (2010), 791–799.
31. Maahs, D.M., Ogden, L.G., Kinney, G.L., Wadwa, P., Snell-Bergeon, J.K., Dabelea, D., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 111 (2005), 747–753.
32. Kumada, M., Kihara, S., Sumitsuji, S., Kawamoto, T., Matsumoto, S., Ouchi, N., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23 (2003), 85–89.
33. Blonde, L., Stenlöf, K., Fung, A., Xie, J., Canovatchel, W., Meininger, G., Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med 128 (2016), 371–380.
34. Petrica, L., Petrica, M., Vlad, A., Dragos Jianu, C., Gluhovschi, G., Ianculescu, C., et al. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121 (2009), 765–775.
35. Sam, S., Haffner, S., Davidson, M.H., D'Agostino, R. Sr., Perez, A., Mazzone, T., Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab 97 (2012), E110–E114.
36. Pfützner, A., Marx, N., Lubben, G., Langenfeld, M., Walcher, D., Konrad, T., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the Pioneer study. J Am Coll Cardiol 45 (2005), 1925–1931.
37. Derosa, G., Bonaventura, A., Bianchi, L., Romano, D., Fogari, E., D'Angelo, A., et al. Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes. Diabet Med 31 (2014), 1515–1523.
38. Derosa, G., Putignano, P., Bossi, A.C., Bonaventura, A., Querci, F., Franzetti, I.G., et al. Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. Eur J Pharmacol 666 (2011), 251–256.